KemPharm (NASDAQ:KMPH) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of KemPharm (NASDAQ:KMPHGet Rating) in a research note published on Thursday morning, MarketBeat reports. The brokerage issued an overweight rating and a $20.00 price objective on the specialty pharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group reduced their price objective on KemPharm from $20.00 to $19.00 in a research note on Thursday, November 10th. Canaccord Genuity Group started coverage on KemPharm in a research note on Thursday, September 15th. They issued a buy rating and a $20.00 price objective on the stock. HC Wainwright cut their target price on KemPharm from $11.00 to $10.00 and set a buy rating on the stock in a research report on Wednesday, August 17th. Finally, StockNews.com downgraded KemPharm from a hold rating to a sell rating in a research report on Friday, November 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus price target of $17.25.

KemPharm Trading Up 4.3 %

NASDAQ:KMPH opened at $4.64 on Thursday. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.14. KemPharm has a 1 year low of $4.00 and a 1 year high of $9.43. The stock’s 50 day simple moving average is $5.68 and its two-hundred day simple moving average is $5.27.

Hedge Funds Weigh In On KemPharm

Large investors have recently modified their holdings of the stock. BlackRock Inc. boosted its holdings in KemPharm by 0.8% during the 1st quarter. BlackRock Inc. now owns 2,253,334 shares of the specialty pharmaceutical company’s stock valued at $11,333,000 after acquiring an additional 17,792 shares during the period. Vanguard Group Inc. boosted its holdings in KemPharm by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,516,912 shares of the specialty pharmaceutical company’s stock valued at $7,630,000 after acquiring an additional 33,367 shares during the period. HealthInvest Partners AB boosted its holdings in KemPharm by 11.9% during the 3rd quarter. HealthInvest Partners AB now owns 750,000 shares of the specialty pharmaceutical company’s stock valued at $4,680,000 after acquiring an additional 80,000 shares during the period. Laurion Capital Management LP purchased a new position in KemPharm during the 2nd quarter valued at $2,597,000. Finally, State Street Corp boosted its holdings in KemPharm by 2.4% during the 1st quarter. State Street Corp now owns 551,615 shares of the specialty pharmaceutical company’s stock valued at $2,775,000 after acquiring an additional 12,798 shares during the period. Institutional investors own 20.85% of the company’s stock.

About KemPharm

(Get Rating)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Featured Articles

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.